Analysts Set NeuroPace, Inc. (NASDAQ:NPCE) Target Price at $14.60

NeuroPace, Inc. (NASDAQ:NPCE) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $14.60.

Several research firms have issued reports on NPCE. Wells Fargo & Company decreased their price target on shares of NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $18.00 price target on shares of NeuroPace in a research note on Wednesday, August 14th.

NeuroPace Stock Up 0.5 %

Shares of NeuroPace stock opened at $10.25 on Monday. The firm has a fifty day moving average of $7.27 and a two-hundred day moving average of $7.28. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The company has a market cap of $305.96 million, a P/E ratio of -10.32 and a beta of 1.79. NeuroPace has a one year low of $5.45 and a one year high of $18.15.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The firm had revenue of $21.06 million during the quarter, compared to the consensus estimate of $19.33 million. During the same period last year, the firm posted ($0.28) EPS. On average, analysts forecast that NeuroPace will post -1 earnings per share for the current year.

Insider Buying and Selling

In related news, major shareholder Ltd. Kck sold 223,991 shares of the firm’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $5.45, for a total value of $1,220,750.95. Following the transaction, the insider now owns 5,270,845 shares in the company, valued at approximately $28,726,105.25. This trade represents a 4.08 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 257,590 shares of company stock valued at $1,437,916. Insiders own 22.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Barclays PLC raised its holdings in NeuroPace by 346.0% in the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after buying an additional 16,007 shares during the period. Geode Capital Management LLC raised its stake in shares of NeuroPace by 8.7% during the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company’s stock valued at $2,211,000 after purchasing an additional 25,330 shares during the period. State Street Corp raised its stake in shares of NeuroPace by 9.1% during the third quarter. State Street Corp now owns 155,490 shares of the company’s stock valued at $1,084,000 after purchasing an additional 12,912 shares during the period. Financial Advocates Investment Management raised its stake in shares of NeuroPace by 20.0% during the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after purchasing an additional 3,000 shares during the period. Finally, Millennium Management LLC raised its stake in shares of NeuroPace by 13.3% during the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock valued at $5,186,000 after purchasing an additional 80,324 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.